SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT04240496

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics in Schizophrenic Patients

Clozapine (Clz), an atypical antipsychotic, is the reference medication for patients with treatment-resistant schizophrenia. Due to the high inter-individual variability of its pharmacokinetics and its narrow therapeutic index, a close therapeutic drug monitoring (TDM) of Clz is highly recommended. Several factors can cause a variation in the pharmacokinetics as age, smoking habits, coffee consumption and drug interaction. Genetic factors related to hepatic expression levels of the cytochrome P450 (CYP), regulate the hepatic clearance of Clz, thereby determine its bioavailability. The CYP1A2 and CYP2C19 isoenzymes are mainly responsible for the metabolism of several drugs including Clz. It has been demonstrated that there is an interethnic variation in the expression and function of these two isoenzymes. This variation is caused by single nucleotide polymorphisms (SNPs) of genes encoding these proteins. While the Influence of the different polymorphisms related to CYP1A2 and CYP2C19 have been established especially in Asian and Caucasian populations, no study has examined the impact of these SNPs in the southern Mediterranean populations. Moreover, the impact of these SNPs is very controversial. The present study aims to investigate in Tunisian schizophrenic patients, the influence of genetic (CYP1A2 and CYP2C19 polymorphisms) and non-genetic factors on Clz pharmacokinetics.

NCT04240496 CYP1A2 Polymorphism CYP2C19 Polymorphism Clozapine Schizophrenia
MeSH:Schizophrenia
HPO:Schizophrenia

1 Interventions

Name: Determination of plasma concentration of clozapine/ Genotyping

Description: Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 & CYP2C19
Type: Other
Group Labels: 1

Schizophrenic patients


Primary Outcomes

Description: Technique : HPLC/UV (high-performance liquid chromatography associated with a UV detector)

Measure: Determination of trough plasma concentration of clozapine (C0)

Time: One and a half months

Secondary Outcomes

Description: - Technique: PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism)

Measure: Determination of the correlation between the presence of CYP1A2*1F (rs762551;-163C> A), CYP1A2*1C (rs2069514;-3860 G> A) and CYP 2C19*2 (rs4244285; 681G>A) and the variability of C0/Daily dose.

Time: One and a half months

Purpose: Supportive Care

Allocation: N/A

Single Group Assignment


There are 3 SNPs

SNPs


1 rs2069514

Determination of the correlation between the presence of CYP1A2*1F (rs762551;-163C> A), CYP1A2*1C (rs2069514;-3860 G> A) and CYP 2C19*2 (rs4244285; 681G>A) and the variability of C0/Daily dose.. - Technique: PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism).


2 rs4244285

Determination of the correlation between the presence of CYP1A2*1F (rs762551;-163C> A), CYP1A2*1C (rs2069514;-3860 G> A) and CYP 2C19*2 (rs4244285; 681G>A) and the variability of C0/Daily dose.. - Technique: PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism).


3 rs762551

Determination of the correlation between the presence of CYP1A2*1F (rs762551;-163C> A), CYP1A2*1C (rs2069514;-3860 G> A) and CYP 2C19*2 (rs4244285; 681G>A) and the variability of C0/Daily dose.. - Technique: PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism).



HPO Nodes


HPO: